Bicocca Open Archive

Logo unimib boa
RIZZARI, CARMELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.866
AS - Asia 6.289
EU - Europa 4.827
SA - Sud America 958
AF - Africa 131
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 8
Totale 22.093
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.284
SG - Singapore 2.305
IT - Italia 1.225
VN - Vietnam 1.137
CN - Cina 1.121
HK - Hong Kong 874
RU - Federazione Russa 792
DE - Germania 746
BR - Brasile 726
IE - Irlanda 487
SE - Svezia 483
CA - Canada 471
UA - Ucraina 219
FR - Francia 200
GB - Regno Unito 173
IN - India 149
BD - Bangladesh 140
FI - Finlandia 130
AR - Argentina 83
AT - Austria 79
ID - Indonesia 75
KR - Corea 75
TR - Turchia 62
NL - Olanda 60
IQ - Iraq 56
MX - Messico 54
CO - Colombia 48
ES - Italia 48
PL - Polonia 47
ZA - Sudafrica 45
PH - Filippine 41
PK - Pakistan 39
SA - Arabia Saudita 37
JP - Giappone 35
EC - Ecuador 31
VE - Venezuela 22
DK - Danimarca 20
EG - Egitto 18
UZ - Uzbekistan 18
CZ - Repubblica Ceca 17
MY - Malesia 16
MA - Marocco 15
AE - Emirati Arabi Uniti 14
BE - Belgio 14
CH - Svizzera 14
CL - Cile 14
KE - Kenya 14
AU - Australia 13
HN - Honduras 13
JO - Giordania 13
PY - Paraguay 12
GR - Grecia 10
BG - Bulgaria 9
IL - Israele 9
PE - Perù 9
RO - Romania 9
BO - Bolivia 8
BZ - Belize 8
TH - Thailandia 8
AL - Albania 7
CR - Costa Rica 7
IR - Iran 7
LB - Libano 7
NO - Norvegia 7
TN - Tunisia 7
ET - Etiopia 6
KZ - Kazakistan 6
PA - Panama 6
CI - Costa d'Avorio 5
DO - Repubblica Dominicana 5
LT - Lituania 5
NP - Nepal 5
OM - Oman 5
PT - Portogallo 5
RS - Serbia 5
AO - Angola 4
AZ - Azerbaigian 4
BW - Botswana 4
BY - Bielorussia 4
DZ - Algeria 4
EU - Europa 4
JM - Giamaica 4
UY - Uruguay 4
BA - Bosnia-Erzegovina 3
DM - Dominica 3
LK - Sri Lanka 3
LV - Lettonia 3
MN - Mongolia 3
NI - Nicaragua 3
PS - Palestinian Territory 3
QA - Qatar 3
SY - Repubblica araba siriana 3
BB - Barbados 2
BH - Bahrain 2
EE - Estonia 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 22.064
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.254
Singapore 1.228
Ashburn 904
Hong Kong 855
San Jose 658
Frankfurt am Main 570
Fairfield 484
Woodbridge 477
Dublin 460
Chandler 387
Milan 363
Toronto 360
Ho Chi Minh City 331
Hanoi 310
Houston 288
New York 288
Wilmington 264
Los Angeles 217
Santa Clara 213
Beijing 211
Dallas 198
Jacksonville 192
Chicago 191
Cambridge 183
Seattle 179
Princeton 176
The Dalles 149
Hefei 137
Dearborn 110
Lauterbourg 100
Rome 97
Buffalo 96
Lawrence 88
Moscow 81
São Paulo 81
Altamura 75
Council Bluffs 68
Seoul 68
Vienna 66
Boardman 63
Munich 56
San Diego 53
Shanghai 52
Helsinki 51
Nanjing 49
Jakarta 46
Haiphong 43
Da Nang 40
London 40
Orem 40
Warsaw 37
Turin 34
Guangzhou 33
Montreal 32
Lachine 31
Rio de Janeiro 31
Nuremberg 30
Tokyo 30
Turku 29
Denver 28
Salt Lake City 28
Phoenix 27
Baghdad 26
Naples 25
Brooklyn 24
Atlanta 23
Chennai 23
Andover 22
Biên Hòa 21
Bogotá 21
Thái Nguyên 21
Brasília 20
Dhaka 20
Johannesburg 19
Lissone 19
Mexico City 19
Stockholm 19
Amsterdam 18
Falls Church 17
Hải Dương 17
Lappeenranta 17
Quận Bình Thạnh 17
Tampa 17
Bologna 16
Boston 16
Can Tho 16
Figino 16
Jeddah 16
Tashkent 16
Washington 16
Buenos Aires 15
Changsha 15
Lahore 15
Shenyang 15
Belo Horizonte 14
Bắc Ninh 14
Elk Grove Village 14
Ha Long 14
Hangzhou 14
Ninh Bình 14
Totale 14.041
Salva come PNG Salva come JPEG
Nome #
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 548
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 465
Acute myeloid leukaemia niche regulates response to L-asparaginase 446
Italian expert consensus recommendations for the safe administration of high-dose methotrexate in children with cancer and for the use of glucarpidase to manage delayed methotrexate elimination and/or high-dose methotrexate-induced acute kidney injury 431
Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis 406
ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells 381
A novel EP300 mutation associated with Rubinstein-Taybi syndrome type 2 presenting as combined immunodeficiency 370
Children with cancer in the time of COVID-19: An 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy 358
Reduced-Intensity delayed intensification in standard-Risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000) 343
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations 323
Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati 315
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study 310
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 307
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 303
Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in non-Hodgkin lymphoma 302
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 295
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 295
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 294
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 292
Eight-year national multicenter experience on the use of glucarpidase as effective rescue therapy for delayed methotrexate elimination after high-dose methotrexate cycles administered in children with hemato-oncological diseases 290
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 290
Mucopolysaccharidosis-Plus Syndrome, a Rapidly Progressive Disease: Favorable Impact of a Very Prolonged Steroid Treatment on the Clinical Course in a Child 277
Screening for Coagulopathy and Identification of Children With Acute Lymphoblastic Leukemia at a Higher Risk of Symptomatic Venous Thrombosis: An AIEOP Experience 275
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 269
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 266
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 265
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica 246
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study 242
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 241
Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study 240
FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia 233
Outcome of very late relapse in children with acute lymphoblastic leukemia 232
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study 232
Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy 230
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica 229
Hermansky-Pudlak syndrome type II and lethal hemophagocytic lymphohistiocytosis: Case description and review of the literature 228
First-Line Postremission Blinatumomab as Successful Toxicity-Sparing Strategy in a Boy with Cystic Fibrosis and Acute Lymphoblastic Leukemia 226
Prognostic value of nephromegaly at diagnosis of childhood acute lymphoblastic leukemia 226
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment 225
Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort 221
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995 219
Williams syndrome and mature B-Leukemia: A random association? 213
Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia 210
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD) 205
Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP‐ALL cell survival and a potential therapeutic target 204
Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia 200
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study 194
Role of DNA index in childhood acute lymphoblastic leukemia treated with BFM based therapy: Long term results of the AIEOP-ALL 95 192
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia 191
A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia 190
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia 186
Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP) 186
Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study 183
Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica 182
Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups 181
Are genotypes of glutathione S-transferase superfamily a risk factor for childhood acute lymphoblastic leukemia? Results of an Italian case-control study 180
ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment 177
Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies 176
Legionellosis in paediatrics [Legionellosi in pediatria] 176
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II 174
Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia 173
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL 172
Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers 170
MTHFR 677C-->T mutation and neural-tube defects 170
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol 164
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial 163
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia 163
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia 159
Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA/ATO 156
Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach 156
Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol 151
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction 151
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war 150
A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1 150
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study 148
Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product 143
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL 139
Collaborative efforts driving progress in pediatric acute myeloid leukemia 138
NUP214–ABL1 fusion in childhood T-ALL 136
Biological therapies in monogenic autoinflammatory diseases: Long-term efficacy and safety 135
Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias 134
Road Traffic Pollution and Childhood Leukemia: A Nationwide Case-control Study in Italy 133
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia 130
Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children with Influenza 129
Nationwide central diagnosis review for childhood solid tumors: From concept to realization of an Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) integrated project 123
Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol 122
Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia 119
Emapalumab in children with primary hemophagocytic lymphohistiocytosis 115
Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial 114
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring 112
Molecularly Targeted Small Molecule Inhibitor Therapy for Pediatric Acute Lymphoblastic Leukemia: A Comprehensive Review of Clinical Trials 110
Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia or acute lymphoblastic leukemia 109
A three-miRNA-based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia 108
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival among Children with High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial 108
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation 107
A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia 104
Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement 104
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study 104
Recommendations by the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) Working Group on preparedness of clinical trials about paediatric medicines process 104
Human Fibrinogen Concentrate and Fresh Frozen Plasma in the Management of Severe Acquired Hypofibrinogenemia in Children with Acute Lymphoblastic Leukemia: Results of a Retrospective Survey 103
Totale 21.165
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.436
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.436
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.311 85 99 105 164 141 135 53 67 106 81 71 204
2022/20231.712 247 528 95 149 112 278 18 82 117 16 44 26
2023/20241.355 83 33 58 69 168 353 275 32 117 22 18 127
2024/20253.880 182 509 210 183 307 94 171 82 462 567 374 739
2025/20269.857 1.099 590 696 959 972 842 1.475 450 635 769 647 723
2026/2027145 145 0 0 0 0 0 0 0 0 0 0 0
Totale 22.673